| BI65 |
Breast |
N9431 |
NCCTG |
CL |
12/31/2001 |
1 |
0 |
0 |
0 |
|
| BP-55 |
Breast |
|
NSABP |
CL |
3/3/1994 |
1 |
0 |
0 |
0 |
|
| BP-56 |
Breast |
|
NSABP |
CL |
10/28/1993 |
1 |
0 |
0 |
0 |
|
| BP-57 |
Breast |
|
NSABP |
CL |
7/23/1999 |
1 |
0 |
0 |
0 |
|
| BP-58 |
Breast |
|
NSABP |
CL |
1/18/2000 |
1 |
0 |
0 |
0 |
|
| CI-66 |
Gastrointestinal |
N9945 |
NCCTG |
CL |
4/8/2005 |
1 |
0 |
0 |
0 |
|
| LTS-01 |
|
|
|
Active |
|
0 |
0.5 |
0 |
|
The research base will not receive credit due to ACS funding of data mngt, stats, etc. |
| NSABP B-18.1 |
Breast |
|
|
CL |
10/30/1993 |
0.1 |
0 |
0 |
0 |
|
| NSABP B-18.2 |
Breast |
|
|
CL |
4/30/1993 |
0.1 |
0 |
0 |
0 |
|
| NSABP B-19 |
Breast |
|
|
CL |
7/31/1990 |
1 |
0 |
0 |
0 |
|
| NSABP B-20 |
Breast |
|
|
CL |
3/5/1993 |
1 |
0 |
0 |
0 |
|
| NSABP B-21 |
Breast |
|
|
CL |
12/31/1998 |
1.5 |
0 |
0 |
0 |
HIGH PRIORITY APPROVAL |
| NSABP B-23 |
Breast |
|
NSABP |
CL |
12/31/1998 |
1 |
0 |
0 |
0 |
|
| NSABP B-23 QOL |
Breast |
|
NSABP |
CL |
12/31/1998 |
0 |
0.5 |
0 |
0 |
QOL STUDY IN WOMEN ON NSABP-B23 |
| NSABP B-24 |
Breast |
|
|
CL |
4/24/1994 |
1.5 |
0 |
0 |
0 |
HIGH PRIORITY APPROVAL; 1.0 CREDIT THRU 5/31/91; 1.5 STARTING 6/1/91 |
| NSABP B-25 |
Breast |
|
|
CL |
2/28/1994 |
1 |
0 |
0 |
0 |
|
| NSABP B-26 |
Breast |
|
NSABP |
CL |
11/26/1996 |
1 |
0 |
0 |
0 |
|
| NSABP B-27 |
Breast |
|
NSABP |
CL |
12/29/2000 |
1 |
0 |
0 |
0 |
|
| NSABP B-27.1 |
Breast |
|
NSABP |
CL |
12/29/2000 |
0.1 |
0 |
0 |
0 |
MARKER STUDY |
| NSABP B-27.2 |
Breast |
|
NSABP |
CL |
12/28/2001 |
0.1 |
0 |
0 |
0 |
BIOMARKER STUDY IN PTS. ON NSABP-B27 |
| NSABP B-28 |
Breast |
|
NSABP |
CL |
|
1 |
0 |
0 |
0 |
|
| NSABP B-29 |
Breast |
|
NSABP |
CL |
12/22/1999 |
1.1 |
0 |
0 |
0 |
0.1 CREDIT FOR MARKER STUDY |
| NSABP B-30 |
Breast |
NSABP-B-30 |
NSABP |
CL |
3/31/2004 |
1 |
0.5 |
0 |
0 |
0.5 CC FOR QOL |
| NSABP B-31 |
Breast |
|
NSABP |
CL |
4/29/2005 |
1.2 |
0 |
0 |
0 |
Additional 0.2 Rx credit for correlative studies (Total = 1.2 Rx credits) |
| NSABP B-32 |
Breast |
|
NSABP |
CL |
2/27/2004 |
1.5 |
0.5 |
0 |
0 |
.5 extra treatment credit assigned; 0.5 cancer control credit for QOL |
| NSABP B-33 |
Breast |
NSABP-B-33 |
NSABP |
CL |
10/9/2003 |
1 |
0.5 |
0 |
0 |
CC credit for QOL |
| NSABP B-34 |
Breast |
NSABP B-34 |
NSABP |
CL |
3/31/2004 |
1.2 |
|
0 |
0 |
|
| NSABP B-35 |
Breast |
NSABP-B-35 |
NSABP |
CL |
6/15/2006 |
1.1 |
0.3 |
0 |
0 |
Cancer Control Credit for QOL |
| NSABP B-36 |
Breast |
NSABP B-36 |
NSABP |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit for QOL; NOTE: QOL component of study closed to accrual as of 8/01/2006 |
| NSABP C-06 |
Gastrointestinal |
|
NSABP |
CL |
3/31/1999 |
1.1 |
0.5 |
0 |
0 |
0.1 FOR MOLECULAR DIAGNOSTICS; 0.5 CREDIT FOR QOL |
| NSABP C-07 |
Gastrointestinal |
|
NSABP |
CL |
11/15/2002 |
1 |
|
0 |
0 |
|
| NSABP C-07.1 |
Gastrointestinal |
|
NSABP |
CL |
7/17/2003 |
|
0.5 |
0 |
0 |
CC Credit to first 400 patients entered via CCOP institutions |
| NSABP P-1 |
Intervention Study |
|
|
Closed |
5/30/1997 |
0 |
1 |
0.3 |
|
1 CR.FOR YR 1;FU CR=0.3; FU CR FOR 6/94-6/95=0.4 |
| NSABP P-1.EXT |
Descriptive |
|
|
Closed |
5/31/2006 |
|
|
0.2 |
|
Credit for this protocl ends as of 12/31/2005. |
| NSABP P-1B.1 |
Intervention Study |
|
|
Closed |
4/1/1998 |
0 |
0.1 |
|
|
|
| NSABP P-1G |
Descriptive |
|
|
Closed |
5/31/2006 |
0 |
0 |
|
|
|
| NSABP P-2 |
Intervention Study |
|
|
Closed |
11/4/2004 |
0 |
1 |
0.3 |
|
0.3 CC CREDIT FOR EACH YEAR ON INTERVENTION AFTER YR 1 |
| NSABP P-2 QOL |
Descriptive |
|
|
Closed |
11/4/2004 |
|
0.3 |
|
|
|
| NSABP R-02 |
Gastrointestinal |
|
|
CL |
12/31/1992 |
1.5 |
0 |
0 |
0 |
HIGH PRIORITY APPROVAL |
| NSABP R-03 |
Gastrointestinal |
|
|
CL |
6/30/1999 |
1 |
0 |
0 |
0 |
|
| NSABP-B-37 |
Breast |
NSABP-B-37 |
NSABP |
AC |
|
1 |
0.5 |
0 |
0 |
CC credit for QOL |
| NSABP-B-38 |
Breast |
NSABP-B-38 |
NSABP |
CL |
5/3/2007 |
1 |
|
0 |
0 |
|
| NSABP-B-39 |
Breast |
NSABP-B-39 |
NSABP |
AC |
|
1 |
0.5 |
0 |
0 |
CC credit for QOL |
| NSABP-B-40 |
Breast |
NSABP-B-40 |
NSABP |
AC |
|
1 |
0 |
0 |
0 |
|
| NSABP-B-42 |
Breast |
NSABP-B-42 |
NSABP |
AC |
|
1 |
0 |
0 |
0 |
|
| NSABP-BP-59 |
Breast |
|
NSABP |
AC |
|
0.1 |
0 |
0 |
0 |
0.1 Treatment Credit per year for 10 years |
| NSABP-C-08 |
Gastrointestinal |
NSABP-C-08 |
NSABP |
CL |
10/6/2006 |
1 |
|
0 |
0 |
|
| NSABP-C-09 |
Gastrointestinal |
NSABP-C-09 |
NSABP |
CL |
10/12/2007 |
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit for QOL |
| NSABP-C-10 |
Gastrointestinal |
|
NSABP |
AC |
|
1 |
0 |
0 |
0 |
|
| NSABP-R-04 |
Gastrointestinal |
NSABP-R-04 |
NSABP |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit for QOL |
| P-1G3 |
|
|
|
Closed |
5/31/2005 |
|
0 |
|
|
No credit assigned to this study |
| P-1G4 |
|
|
|
Closed |
5/31/2005 |
0 |
0 |
|
|
Ancillary study with no credit |
| P-3 |
Intervention Study |
|
|
Closed |
4/3/2006 |
0 |
1 |
0.3 |
3 |
|
| P-3 QOL |
Intervention Study |
|
|
Closed |
4/3/2006 |
0 |
0.3 |
0 |
0 |
|